SPOTLIGHT -
Understanding and Managing Behavioral and Psychological Symptoms of Dementia
Recognition is the first and most important step to treating behavioral and psychological symptoms of dementia.
Honoring Memorial Day: The Latest on the Military, Grief, and PTSD
In honor of Memorial Day...
“I Know It When I See It”: Definitions of Treatment-Resistant Depression
Presenters at the 2023 APA Annual Meeting compared definitions of treatment-resistant depression.
Categorizing the Jewish History of Resilience
Psychiatric Times’ very own H. Steven Moffic, MD, spoke about resilience and religion at the 2023 APA Annual Meeting.
Issues in the Military: A Conversation with Elspeth Ritchie, MD
Learn more about women’s issues, suicide, and PTSD in the military.
Tardive Dyskinesia, Huntington Disease Chorea Treatment Now Available
Deutetrabenazine extended-release tablets are now available.
Things To Do in San Francisco While You Are Visiting for the 2023 APA Annual Meeting
Here are some things to check out in the city while you're in town...
FDA Approves First Treatment for Agitation Associated With Alzheimer Disease Dementia
Brexpiprazole has been approved by the US Food and Drug Administration for the treatment of agitation associated with Alzheimer disease dementia.
NDA Approved for Long-Acting Injectable for Schizophrenia and Bipolar I
Aripiprazole will be the first 2-month LAI antipsychotic indicated for both the treatment of schizophrenia and the maintenance treatment of bipolar I disorder in the United States.
Phase 2/3 Study Begins for Generalized Anxiety Disorder Agent
Ulotaront, a trace amine-associated receptor 1 agonist with 5-HT1A agonist activity, is under investigation for the treatment of generalized anxiety disorder.
Positive Results for Lumateperone in Patients With Mixed Features in Major Depressive Disorder, Bipolar Depression
New results for a study evaluating lumateperone.
Evenamide for Treatment-Resistant Schizophrenia
Recent research evaluated evenamide as an add-on to an antipsychotic for patients with treatment-resistant schizophrenia.
Earthquake Relief Efforts: Frontline Heroes
We connected with a group working on the frontlines of Southern Turkey and Northern Syria to assist the survivors of the devastating earthquake.
Report Reveals More Than 50% of Americans Misuse At-Home Ketamine
The Future of Mental Health: Ketamine Therapy Report revealed that 55% of Americans who tried at home ketamine took more than the recommended dose.
Neuromodulation Device for Depression Granted Breakthrough Device Designation
Transcranial direct current stimulation for depression.
Alzheimer Disease: Are the Treatments Worse Than the Illness?
What are the available and upcoming AD treatments and how can you utilize them to best serve your patients?
New Tool for Assessing the Impact of Tardive Dyskinesia
A new, easy-to-use scale might be able to help clinicians determine the impact of tardive dyskinesia on patient functioning.
Positive Results from Phase 2a Trial of Psychedelic for Major Depressive Disorder
SPL026 with supportive therapy sees positive results in patients with major depressive disorder.
NDA Accepted for Nasal Nalmefene for Opioid Overdose
The FDA has accepted the NDA for nasal nalmefene, OPNT003, to treat opioid overdose.
25 Years of Poetry of the Times
Celebrating 25 years of Poetry of the Times with Richard Berlin, MD!
FDA-Approved: Risperidone Extended-Release Injectable Suspension
New approval for schizophrenia and bipolar I disorder.
Mental Health Deserts for American Indians and Alaska Natives
How can you better provide care for American Indians and Alaska Natives?
Trial of ADHD Medication with Fast Onset of Action, Entire Active Day Efficacy Initiated
The first phase 3 clinical trial of CTx-1301 for the treatment of ADHD has begun.
Virtual Reality for Patients With Schizophrenia
VR-based training may help improve social cognition and functioning in patients with schizophrenia.
Cariprazine FDA-Approved as Adjunctive Therapy to Antidepressants
Cariprazine is now FDA-approved as an adjunctive therapy to antidepressants.
Dementia in the News
What's the latest in dementia?
Predicting Daytime Sleepiness & Fatigue Post-Stroke
Cognitive and psychiatric symptoms at 3 months post-stroke might predict daytime sleepiness and fatigue at 12 months.
Psychopharmacology Conference Offers New Research, Prescribing Tips
Check out the best clinical pearls from the 2022 Neuroscience Education Institute (NEI) Congress!
Air Pollution Affects Depressive Symptoms in Bipolar Disorder
New research indicates worsened air quality leads to increased depressive symptoms in patients with bipolar disorder.
Identifying the Symptom of Worthlessness to Prevent Suicide in Adolescents With ADHD
Screening for the symptom of worthlessness could save your adolescent patient’s life…
